Primary Erythromelalgia
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Xenon PharmaceuticalsBC - Burnaby
2 programsXPF-001PHASE_1_21 trial
XPF-002PHASE_1_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Xenon PharmaceuticalsXPF-002
Xenon PharmaceuticalsXPF-001
Clinical Trials (2)
Total enrollment: 12 patients across 2 trials
Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Start: Dec 2011Est. completion: May 20128 patients
Phase 1/2Completed
Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)
Start: Apr 2010Est. completion: Sep 20104 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.